Sign in
Active, not recruitingNo phase

The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)

Key facts

Who runs it
Copenhagen University Hospital, Rigshospitalet
Where
Denmark2 sites in 1 countryChoose a country to see its sites
Status
Active, not recruiting
People taking part
352 people enrolled
Started
1 May 2021
Expected to end
1 Apr 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Rivaroxaban
  • Acetylsalicylic acid
  • Clopidogrel
  • Edoxaban
  • Dabigatran
  • Apixaban
  • Warfarin
Record updated
6 April 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Patients who underwent successful TAVI according to Valve Academic Research Consortium (VARC)-2 criteria
  • Residing in Denmark
  • Provided written informed consent

Who cannot take part

  • Atrial fibrillation or any other indication for lifelong oral anticoagulant therapy
  • Patient deemed not suitable for DOAC treatment because of previous life-threatening or major bleeding, e.g. intracranial haemorrhage or major gastrointestinal bleeding
  • Patient with absolute indication for anti-thrombotic therapy, e.g. recent PCI
  • Iodine contrast allergy or other condition that prohibits CT imaging
  • Patients with severe renal insufficiency (eGFR <30 mL/min/1.73 m2)
  • Age <18 years
  • Women of childbearing potential, pregnant or nursing

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

A randomized clinical trial investigating the incidence and temporal dynamics of subclinical leaflet thickening by cardiac CT in transcatheter bioprosthetic aortic valves in patients randomised to different anti-thrombotic strategies. Additionally, this study aims to examine a possible association between HALT and thromboembolic events.

The 2 groups in the trial

  • Sinus rhythm - DOAC treatmentTreatment being tested

    Can either of the following anti-platelet components: dabigatran, apixaban, rivaroxaban, edoxaban or warfarin. Duration: 3 months, followed by an anti-platelet hereafter.

    Treatment: Rivaroxaban, Edoxaban, Dabigatran, Apixaban, and Warfarin

  • Sinus rhythm - Anti-platelet treatmentExisting treatment, for comparison

    Can be either of the following anti-platelet components: acetylsalicylic acid or clopidogrel. Duration: Lifelong

    Treatment: Acetylsalicylic acid and Clopidogrel

Results explained

A paper that names this trial, explained in plain words.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prospective Study on the Impact of Different Anti-thrombotic Therapies on Subclinical Leaflet Thickening and Its Temporal Dynamics in Transcatheter Bioprosthetic Aortic Valves (NOTION-4)
Publications
Record updated
6 April 2025